Dow Jones
38.460,92 -42,77 (-0,11%) Nasdaq
15.712,75 +16,11 (+0,10%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0727 +0,0026 (+0,25%) Bitcoin EUR
59.911,45 -2.346,27 (-3,77%) CMC Crypto 200
1.390,44 +7,87 (+0,57%)
IGM Biosciences, Inc. (IGMS)
Dopo ore:
| Chiusura precedente | 7,70 |
| Aperto | 7,76 |
| Denaro | 7,92 x 200 |
| Lettera | 7,98 x 100 |
| Min-Max giorno | 7,75 - 8,60 |
| Intervallo di 52 settimane | 3,81 - 17,70 |
| Volume | |
| Media Volume | 271.329 |
| Capitalizzazione | 467,941M |
| Beta (5 anni mensile) | 0,25 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -4,71 |
| Prossima data utili | 10 mag 2024 - 14 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 21,22 |
GlobeNewswireIGM Biosciences Announces Retirement of Chairman Michael Loberg, Ph.D. from Board of Directors and Appointment of Elizabeth H.Z. Thompson, Ph.D. to Board of Directors
MOUNTAIN VIEW, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Michael Loberg, Ph.D. has retired from its Board of Directors, including as Chairman, effective October 3, 2023. Dr. Loberg has served as a member of the IGM Biosciences Board of Directors since 2015 and as Chairman of the Board since 2018. IGM Biosciences is also pleased to announc
- GlobeNewswire
IGM Biosciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
MOUNTAIN VIEW, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 9:30 a.m. EDT. A live audio webcast of the event will be available on the “Events and Presentations” page
- GlobeNewswire
IGM Biosciences Announces Second Quarter 2023 Financial Results
– Continued progress in clinical development across portfolio –– Public equity offering and concurrent private placement with gross proceeds of $120.0 million – MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023. “We continued to make good progress in the development of our IgM pl
